Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2024.2319607 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Cheng Ean Chee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore. Hauptthemen laut MEDLINE: Bevacizumab, Sorafenib, Cost-Benefit Analysis, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Roche Singapore Pte Ltd.
Abstract (Originalsprache)
OBJECTIVES: This study aims to explore the cost-effectiveness of atezolizumab plus bevacizumab against sorafenib for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) in Singapore. METHODS: A partitioned survival model was developed from a healthcare system perspective, with a 10-year lifetime horizon. Clinical inputs and utilities were obtained from the IMbrave150 trial. Healthcare resource use costs were obtained from published local sources; drug costs reflected the most recent public hospital selling prices. Outcomes included life years, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses were performed to assess the model's robustness. RESULTS: Atezolizumab plus bevacizumab offered an additional 1.42 life years and 1.09 QALYs, with an additional cost of S$111,847; the ICER was S$102,988/QALY. The World Health Organization considers interventions with ICERs
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore.
- Medical, Roche Singapore Pte Ltd, Singapore, Singapore.
- Market Access, Roche Singapore Pte Ltd, Singapore, Singapore.
- Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore.
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Förderung
- Roche Singapore Pte Ltd
Zitieren
APA
Chee, C. E., Khara, J. S., Cheong, J., Fong, J., Sivanesan, S., Choy, J. Y., Hu, M., Viswambaram, A., & Toh, H. C. (2024). Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2319607
Vancouver
Chee CE, Khara JS, Cheong J, Fong J, Sivanesan S, Choy JY, et al. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2319607
BibTeX
@article{Chee2024,
author = {Chee, Cheng Ean and Khara, Jasmeet Singh and Cheong, John and Fong, Jek and Sivanesan, Sivabalan and Choy, Jian Yi and Hu, Meibo and Viswambaram, Amrita and Toh, Han Chong},
title = {Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2024.2319607}
}
EUVIMED